by The PD-1 and PD-L1 Inhibitor Market is estimated to be valued at US$ 39.83 Bn in 2023 and is expected to exhibit a CAGR of 14.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
PD-1 and PD-L1 inhibitors are cancer immunotherapy drugs that inhibit programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) interaction which allows T cells to destroy cancer cells. These inhibitors have demonstrated success in the treatment of various types of cancers such as melanoma, lung cancer, renal cell carcinoma, Hodgkin’s lymphoma, and others. They enhanced survival rates and witnessed fast approval by regulatory agencies for their effectiveness against hard-to-treat cancers.
Market Dynamics:
The PD-1 and PD-L1 inhibitor market is witnessing robust growth owing to rising cancer incidences globally. According to the WHO, cancer burden rose to 19.3 million new cases and 10.0 million cancer deaths in 2020. Such high prevalence is propelling the demand for efficient cancer therapies like PD-1 and PD-L1 inhibitors. Furthermore, continuous pipeline developments and approvals for new indications are also boosting the market. For instance, in 2021, Merck received FDA approval for Keytruda in the frontline treatment ofstage III non-small cell lung cancer and recurrent or metastatic cervical cancer. In addition, increasing adoption of combination therapies involving PD-1 and PDL-1 inhibitors with chemotherapy, radiation therapy, targeted therapies is further promoting the market growth. However, high cost of immunotherapy drugs and complex manufacturing processes remain key challenges.
Segment Analysis
The global PD-1 and PD-L1 inhibitor market is dominated by thePD-1 inhibitors segment. PD-1 inhibitors such as Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo have shown superior and durable clinical benefits over chemotherapy or targeted therapy alone for lung cancer, melanoma, renal cell carcinoma, and other cancers.
PEST Analysis
Political: Government support in the form of regulatory approvals and favorable healthcare reforms will help drive the PD-1 and PD-L1 inhibitor market growth.
Economic: Rising disposable income and growing healthcare spending are increasing the affordability of premium cancer treatments such as PD-1 and PD-L1 inhibitors among cancer patients.
Social: Growing cancer prevalence along with increasing public awareness about immunotherapies is boosting the demand for PD-1 and PD-L1 inhibitors.
Technological: Advancements in bioinformatics techniques are helping identify new cancer antigens that can potentially be targeted by PD-1 and PD-L1 inhibitors.
Key Takeaways
The global PD-1 And PD-L1 Inhibitor Market Share is expected to witness high growth, exhibiting 14% CAGR over the forecast period of 2023 to 2030, due to increasing adoption of immunotherapies over conventional cancer therapies. The market size for 2023 is estimated to reach US$ 39.83 billion.
Regionally, North America holds the largest share in the PD-1 and PD-L1 inhibitor market and is expected to maintain its dominance over the forecast period due to rising prevalence of cancer and faster adoption of premium therapies in the region. Asia Pacific is expected to be the fastest growing market owing to improving access to innovative therapies and increasing healthcare spending.
Key players operating in the PD-1 and PD-L1 inhibitor market are Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, and Regeneron Pharmaceuticals Inc. Among them, Merck & Co. leads the market with its blockbuster drug Keytruda, which has gained widespread adoption for treating lung cancer, melanoma and several other cancer types.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.
